Improving Risk Assessment of Acute Myeloid Leukemia (AML) With a Precision Genomic
Strategy to Assess Mutation Clearance
In patients who have been treated with standard consolidation chemotherapy and cleared
their leukemia-associated mutations, is relapse-free and overall survival superior
to what is expected based on historical controls?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
The investigators will prospectively determine whether the relapse-free and overall
survival in patients who have cleared their leukemia-associated mutations treated
with standard consolidation chemotherapy is superior to what is expected based on
historical controls. The investigators will also prospectively determine the relapse-free
and overall survival of patients who have not cleared their mutations. Because the
relapse rate of patients with persistent mutations is expected to be high, treatment
with either standard of care consolidation therapy alone or alloSCT will be permitted,
at the discretion of the treating physician.
Study Reference #: ULEU18122
Lead Researcher (Principal Investigator)
Lead Researcher: Eric Huselton
Study Contact InformationStudy Coordinator: Haley Misch
Phone: (585) 275-9485
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search